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P
roteins have demonstrated great
value as research tools and as hu-
man therapeutics. Due to the inabil-
ity of virtually all proteins to spontaneously
enter cells, however, exogenous proteins
are predominantly restricted to interaction
with extracellular targets and targets acces-
sible through the endocytic pathway. Over
thepastdecade,avarietyofreagentsforthe
delivery of proteins into mammalian cells
have been developed including lipid-linked
compounds (1), nanoparticles (2), and fu-
sions to receptor ligands (3, 4). Perhaps the
most commonly used method for protein
delivery is genetic fusion to protein trans-
duction domains (PTDs) including the HIV-1
transactivator of transcription (Tat) peptide,
oligoarginine, and the Drosophila
Antennapedia-derived penetratin peptide
(5, 6). Despite these advances, intracellular
targets remain difﬁcult to perturb using ex-
ogenousproteins;evenmodestsuccesscan
require high concentrations of exogenous
protein because of the limited potency of
most current methods. Challenges for pro-
tein delivery are signiﬁcantly increased in
vivo, where cells in the context intact tissues
and organs have proven especially difﬁcult
targets for functional protein delivery (7, 8).
The development of more potent protein
transduction platforms would therefore sig-
niﬁcantly increase the scope of potential ap-
plications for protein reagents and
therapeutics.
We recently described “supercharged”
GFP variants that have been extensively mu-
tated at their surface-exposed residues, re-
sulting in extremely high theoretical net
charge magnitudes ranging from 30 to
48 (9). We discovered that superpositively
charged GFP variants can enter a variety of
mammalian cells by binding to anionic cell-
surface proteoglycans and undergoing en-
docytosis in an energy-dependent and
clathrin-independent fashion (10). Further,
we observed that superpositive GFPs are
able to form stable noncovalent complexes
with nucleic acids and that 36 GFP can de-
liver siRNA and plasmid DNA into a variety
of mammalian cell lines without apparent
cytotoxicity.
We hypothesized that 36 GFP may also
serve as a potent and general platform for
the delivery of proteins into mammalian
cells.Webeganbygeneratingavarietyoffu-
sion proteins with 36 GFP and observed
that these fusions maintain the ability to
rapidly (within 15 min) and potently (at low
nanomolar concentrations) penetrate mam-
malian cells without toxicity (Supplementary
Figures 13).
Next we directly compared the ability of
36 GFP, Tat, Arg10, and penetratin to de-
liver fused mCherry (11), a red ﬂuorescent
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ABSTRACT The inability of proteins to po-
tently penetrate mammalian cells limits their
usefulness as tools and therapeutics. When
fused to superpositively charged GFP, proteins
rapidly (within minutes) entered ﬁve different
types of mammalian cells with potency up to
100-fold greater than that of corresponding fu-
sions with known protein transduction domains
(PTDs) including Tat, oligoarginine, and penetra-
tin. Ubiquitin-fused supercharged GFP when in-
cubated with human cells was partially deubiq-
uitinated, suggesting that proteins delivered
with supercharged GFP can access the cytosol.
Likewise, supercharged GFP delivered func-
tional, nonendosomal recombinase enzyme
with greater efﬁciencies than PTDs in vitro and
also delivered functional recombinase enzyme
to the retinae of mice when injected in vivo.
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mCherry, Tat-mCherry, Arg10-mCherry, and
penetratin-mCherry with identical linkers
and fusion orientations (Supplementary
Figure 4), and incubated these four fusion
proteins with HeLa cells, baby hamster kid-
ney cells (BSR cells, a clone of BHK-21
cell line), NIH 3T3 cells, inner medullary
collecting duct (IMCD) cells, and rat pheo-
chromocytoma PC12 cells in serum-free
media at various concentrations for4ha t
37 °C.
After incubation, cells were washed un-
der conditions conﬁrmed to remove surface-
bound protein (Supplementary Figure 5),
trypsinized, and assayed for internalized
mCherry by ﬂow cytometry (Figure 1,
panel a). For all ﬁve cell lines and at all con-
centrations tested (10 nM to 2 M), 36
GFP delivered 10- to 100-fold more
mCherry than Tat or Arg10. At concentra-
tions of 100 nM, 36 GFP also delivered
6- to 20-fold more mCherry than penetra-
tin, which approached the potency of 36
GFP only in HeLa cells and only at the high-
est tested concentrations (1 and 2 M).
These results suggest that 36 GFP is a sig-
niﬁcantly more potent protein transduction
agent than the widely used Tat, Arg10, and
penetratin, especially at submicromolar
concentrations. We also observed that the
presence of serum in culture media mod-
estly decreased (2-fold reduction in me-
dia containing 50% serum compared with
media lacking serum) but did not abrogate
the delivery of 36 GFP-mCherry into cells
(Supplementary Figure 5). Delivery of
mCherry into cells by 36 GFP was con-
ﬁrmed by live-cell confocal ﬂuorescence mi-
croscopy (Figure 1, panel b) and by compari-
son with control experiments in which
endocytosis is blocked at 4 °C and protein
remains surface-bound (Supplementary Fig-
ure 6).
To study the ability of proteins delivered
with 36 GFP to access the cytosol, we gen-
erated a ubiquitin-36 GFP fusion in which
the C-terminus of ubiquitin was directly fol-
lowed by 36 GFP. A direct fusion of this
type is recognized and processed by cytoso-
lic deubiquitinases (DUBs), and DUB-
dependent deubiquitination has previously
been used as an indicator of cytosolic expo-
sure (12, 13). A mutant form of ubiquitin
(G76V) that is not a substrate for DUBs (12)
was similarly fused to 36 GFP to distin-
guish the effect of cytosolic DUBs from non-
speciﬁc proteolysis.
Aftera1ho fincubation of HeLa, 3T3, or
BSR cells with either 100 nM ubiquitin-36
GFP or 100 nM ubiquitin G76V 36 GFP, a
signiﬁcant fraction (HeLa, 25  5.8%; 3T3,
272.4%;BSR:244.0%)ofinternalized
Figure 1. Comparison of mCherry delivery by 36 GFP, Tat, Arg10, and penetratin. a) Flow cytometry of HeLa, BSR, 3T3, PC12, and IMCD
cells incubated in the presence of the speciﬁed concentrations of 36 GFP-mCherry, Tat-mCherry, Arg10-mCherry, penetratin-
mCherry, or wild-type mCherry alone for4ha t3 7° C .Cells were washed three times with 20 U mL1 heparin in PBS to remove
membrane-bound protein before analysis. Error bars represent the standard error of three independent biological replicates. b) Confo-
cal ﬂuorescence microscopy of live cells incubated with 100 nM 36 GFP-mCherry for4ha t3 7° C .R e dcolor represents mCherry sig-
nal; green color represents 36 GFP signal. The scale bar is 15 m.
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protein equal in size to 36 GFP (Figure 2,
panel a). In contrast, in all cases the G76V
mutant-36 GFP fusion was not apprecia-
bly cleaved, indicating that this reduction in
size does not arise from nonspeciﬁc endo-
somal proteases but instead from the action
of DUBs. Ubiquitin-36 GFP spiked into
the cell lysis buffer prior to harvesting un-
treated cells was not cleaved (Figure 2,
panel a), indicating that the observed deu-
biquitination is a result of exposure to cyto-
solic DUBs and not due to contact with
DUBs during the cell-harvesting procedure.
Additionally, ubiquitin-36 GFP was com-
pletely deubiquitinated when incubated in
HeLa cytosolic extract for 1 h, while the
DUB inhibitors N-ethylmaleimide (14)
and ubiquitin-aldehyde (15) blocked de-
ubiquitination (Figure 2, panel b), further
suggesting that the cleavage of ubiquitin-
36 GFP is a result of DUB activity. Collec-
tively, these results demonstrate that some
of the ubiquitin-36 GFP protein fusion can
access cytosolic enzymes in three distinct
mammalian cell lines.
Next we compared the ability of 36
GFP, Tat, Arg10, and penetratin to deliver a
functional enzyme, Cre recombinase, into a
variety of mammalian cells. Exogenously de-
livered Cre must escape the endosome, lo-
calize to the nucleus, and tetramerize to me-
diate DNA recombination (16). We
generated 36 GFP-Cre, Tat-Cre, Arg10-Cre,
and penetratin-Cre fusion proteins (Supple-
mentary Figure 7) and tested their ability to
effect recombination in HeLa cells tran-
siently transfected with pCALNL-DsRed2
(17), a DsRed2-based Cre activity reporter
plasmid. After incubation with 1001000
nM of each Cre fusion protein for4hi n
serum-free media, cells were washed to re-
move surface bound protein and incubated
in full media for 48 h. Delivery of Cre was as-
sayed by following DsRed2 expression us-
ing ﬂow cytometry and ﬂuorescence micros-
copy (Figure 3, panel a). We observed that
36 GFP-Cre generated 2- to 5-fold more
recombinants than the corresponding fu-
sions with Tat, Arg10, or penetratin.
Cre delivery was further evaluated in a
NIH-3T3 cell line harboring an integrated
lacZ-based Cre-reporter (5). After incuba-
tion, treatment, and washing as described
above,thesecellswerestainedwithX-Galto
identify recombinants. Consistent with the
HeLa cell results, 36 GFP-Cre resulted in
more efﬁcient generation of recombinants
than Tat, Arg10, or penetratin. The efﬁcacy of
36 GFP-Cre was 10- to 100-fold higher
than that of the other Cre fusions at 100
nM, 10-fold higher at 500 nM, and 5-fold
higher at 1 M (Figure 3, panel b). These
ﬁndings together indicate that 36 GFP can
deliver substantially more functional Cre
than Tat, Arg10, or penetratin in these cell
lines.
Next, we used BSR cells to generate a
Cre reporter cell line conditionally express-
ing the tdTomato ﬂuorescent protein after
Cre-mediated DNA recombination. Follow-
ing treatment as described above, Cre-
mediated recombination was quantiﬁed by
ﬂow cytometry. In this cell line, 36 GFP
was 2- to 15-fold more effective than Arg10
or penetratin. At low concentrations, 36
GFP delivered modestly higher levels of
functionalCrethanTat,whilehigherconcen-
trations of Tat-Cre generated 2-fold more
recombinants than 36 GFP-Cre. This cell
line exhibits unusual features, including a
high metabolic rate (doubling time  12
h( 18)), which led us to speculate that endo-
somal trafﬁcking to lysosomes may be un-
usually efﬁcient in these BSR cells com-
pared with HeLa- and 3T3-based reporter
cells. Indeed, when BSR cells were incu-
bated with the Cre fusions in the presence
Figure 2. Deubiquitination suggests cytosolic exposure of a ubiquitin-36 GFP fusion protein.
a) Western blots using anti-GFP antibodies. Lanes 13: puriﬁed protein samples of 36 GFP,
wild-type ubiquitin-36 GFP fusion (wt), or G76V mutant ubiquitin-36 GFP fusion (mut). Lanes
4 and 5: puriﬁed protein spiked into HeLa cell lysate to conﬁrm that lysis conditions do not af-
fect fusion protein integrity. Lanes 611: the indicated cells were treated with 100 nM of either
the wt or mutant ubiquitin-36 GFP for 1 h and then lysed. b) Mean extent of deubiquitination
of wt ubiquitin-36 GFP fusion protein in HeLa, 3T3, and BSR cells. Error bars reﬂect the stan-
dard deviation of three independent biological replicates. c) In vitro deubiquitination control ex-
periment. Ubiquitin-36 GFP fusion proteins were incubated in either HeLa cytosolic extract or
in HeLa cytosolic extract containing one of two DUB inhibitors, 10 mM N-ethylmaleimide (NEM)
or 20 gm L 1 ubiquitin-aldehyde (Ub-Al), for1ha t3 7° C .
LETTER
www.acschemicalbiology.org VOL.5 NO.8 • 747–752 • 2010 749of 100 M chloroquine, an inhibitor of lyso-
somal protein degradation (19), we ob-
served a dramatic increase in the number
of recombinants arising from 36 GFP-Cre
treatment and modest improvements for
Tat-Cre, Arg10-Cre, and penetratin-Cre, such
that at all concentrations tested 36 GFP-
Cre delivered more recombinase activity
than any of the other proteins (Figure 3,
Figure 3. Delivery of active Cre recombinase into mammalian cells in vitro and in vivo. a) Cre-mediated recombination in HeLa cells tran-
siently transfected with pCALNL-DsRed2 and treated with 36 GFP-Cre, Tat-Cre, Arg10-Cre, or penetratin-Cre for4ha t3 7° C .T h eimage is
an overlay of DsRed2 signal and brightﬁeld images of HeLa cells transfected with pCALNL-DsRed2 and treated with 100 nM 36 GFP-
Cre. b) Cre-mediated recombination in 3T3.LNL.LacZ cells treated with 36 GFP-Cre, Tat-Cre, Arg10-Cre, or penetratin-Cre for4ha t3 7° C .
The image is of 3T3.loxP.lacZ cells treated with 500 nM 36 GFP-Cre and stained with X-Gal. c) Cre-mediated recombination in BSR.LNL.
tdTomato cells treated with 36 GFP-Cre, Tat-Cre, Arg10-Cre, or penetratin-Cre for4ha t3 7° C .T h eimage is an overlay of tdTomato signal
and brightﬁeld images of BSR.LNL.tdTomato cells treated with 100 nM 36 GFP-Cre. d) Identical to panel c but with the addition of
100 M chloroquine during and after protein treatment. In panels ad, error bars reﬂect the standard error of three independent biologi-
cal replicates. e) Fluorescence microscopy of a retinal section of a CD1 adult mouse injected with 0.5 Lo f1 0 0M 36 GFP. The retina
was harvested and analyzed 6 h after injection. GFP ﬂuorescence is shown in green, and DAPI nuclear stain is shown in blue. f) Retinal
sections of neonatal RC::PFwe mouse pups harboring a nuclear LacZ reporter of Cre activity. Three days after injection of 0.5 Lo f4 0M
wild-type Cre, Tat-Cre, or 36 GFP-Cre, retinae were harvested, ﬁxed, and stained with X-gal. Dots on the graph represent the total
number of recombined cells counted in each retina. The horizontal bar represents the average number of recombined cells per retina for
each protein injected (n  4 for wild-type Cre, n  6 for Tat-Cre, n  6 for 36 GFP-Cre).
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unique cell-penetration potency of 36
GFP can be more fully exploited by extend-
ing the time available for internalized pro-
tein to escape endosomes, resulting in even
higher levels of delivered functional pro-
tein. In support of this hypothesis, in vitro
assays reveal that while 36 GFP-Cre is not
active as the intact fusion (Supplementary
Figure 7), at pH 5.56.5 cathepsin B, a
ubiquitous mammalian endosomal pro-
tease, will cleave 36 GFP-Cre to generate
36 GFP and active Cre (Supplementary Fig-
ures 7 and 8). At pH 5.0, the exopeptidase
activity of cathepsin B is maximized (20),
and we observed complete degradation of
Cre and the loss of recombinase activity in
vitro (Supplementary Figure 8). These ﬁnd-
ings are consistent with a model in which
choloroquine’s ability to prevent complete
acidiﬁcation of lysosomes (21) extends the
endosomal lifetime of active Cre and
therebyenablesalargeramountoftheinter-
nalized enzyme to escape endosomes.
Finally, we tested 36 GFP as a protein
delivery agent in vivo. First we examined the
tissue penetration of 36 GFP in the adult
mouse retina. We injected 0.5 Lo f1 0 0M
36 GFP into the subretinal space of CD1
adult mice. After 6 h, the retinae were har-
vested and analyzed by ﬂuorescence mi-
croscopy (Figure 2, panel d). Most of 36
GFP signal was observed near the photore-
ceptoroutersegments,butsigniﬁcantsignal
was observed throughout the retina, includ-
ing all three nuclear layers (the outer, inner,
and ganglion cell layers) as well as in the
cellprocesses.Totesttheabilityof36GFP
to deliver functional protein in vivo,w ei n -
jected 36 GFP-Cre into the subretinal
space of RC::PFwe mouse p0 pups contain-
ingaLoxP-ﬂankedtranscriptionalterminator
upstream of a nuclear lacZ reporter gene
(22). Three days after injection of 0.5 Lo f
40 M wild-type Cre, Tat-Cre, or 36 GFP-
Cre, retinae were harvested, ﬁxed, and
stained with X-gal (Figure 2, panel e). Injec-
tionof36GFP-Cregeneratedanaverageof
715 recombined cells per injected retina
(n6),Tat-Cregeneratedanaverageof318
recombined cells (n  6), and wild-type Cre
generated an average of 117 recombined
cells per retina (n  4). To our knowledge,
this is the ﬁrst report of functional delivery
of an enzyme into retinal cells in vivo.
We also performed additional complete
sets of mCherry and Cre delivery experi-
ments in vitro using 36 GFP, Tat, and oli-
goarginine fusion proteins constructed with
linkers and fusion orientations distinct from
the examples presented above. For both
sets of additional experiments we observed
results that are qualitatively similar to those
in Figures 13 (Supplementary Figures 9
and 10). The delivery of mCherry by 36
GFP in these alternative fusion proteins was
10- to 100-fold more potent than mCherry
delivery by either Tat or oligoarginine, and
the delivery of functional Cre recombinase
by 36 GFP in these alternative fusion pro-
teinswas3-to5-foldmorepotentthanCre
delivery by Tat or oligoarginine. These re-
sults collectively indicate that the ﬁndings
described in this work are not unique to a
speciﬁc protein construct but instead are
more generally applicable.
In conclusion, side-by-side comparisons
of 36 GFP, Tat, Arg10 and penetratin fused
tomCherryorCrerecombinaserevealedthat
fusions with supercharged GFP result in dra-
matically higher levels of internalized pro-
tein (up to 100-fold) and in signiﬁcantly
greater efﬁciencies of Cre-induced recombi-
nation (up to 10-fold) than three currently
used protein transduction domains in a va-
riety of mammalian cell lines. Functional Cre
recombinase can also be delivered to cells
upon injection in vivo using 36 GFP. These
results collectively demonstrate the poten-
tial of supercharged proteins as an unusu-
ally potent in vitro and in vivo protein deliv-
ery platform.
METHODS
For complete experimental methods including
details of cell lines, cell culture, protein puriﬁca-
tion, deubiquitination assay, and all sequences
of all proteins, see Supporting Information.
Live-Cell Imaging. Cells were plated onto 35-mm
glass-bottom microwell dishes with a No. 1.5 cover
glass (MatTek) at a density of 106 cells per plate.
After 18 h, cells were washed once with cold PBS
and incubated with protein in serum-free DMEM.
After incubation, cells were washed three times
with cold 20 U mL1 heparin in PBS to remove
membrane-bound protein, imaged in prewarmed
HEPES imaging solution (1 mM MgCl2, 5 mM KCl,
5 mM CaCl2, 150 mM NaCl, 1.9 g L1 glucose, 1.9 g
L1 albumin, 20 mM HEPES, pH 7.4, 37 °C). Cells
were imaged on an Olympus IX71 spinning disk
confocal microscope on a heated stage with a
100X objective lens. GFP and mCherry were visual-
ized with a 491 and 561 nm excitation laser, re-
spectively. Images were prepared using OpenLab
software.
For live-cell images of Cre reporter cells, cells
were treated with 500 nM 36 GFP-Cre as de-
scribed below for analysis of Cre recombination
and imaged on an Olympus IX51 ﬂuorescent mi-
croscope with a DP30BW black and white camera.
Images are false-color overlays of the ﬂuorescent
signal on a bright-ﬁeld image. LacZ-positive cells
were imaged on an IX70 microscope under bright-
ﬁeld illumination with a DP70 camera.
Flow Cytometry and mCherry Delivery Assays.
Cells were plated onto a 48-well plate at a den-
sity of 5  105 cells per well. After 18 h, cells were
washed once with cold PBS and incubated with
protein in serum-free DMEM. After incubation, cells
were washed three times with cold 20 U mL1 he-
parin in PBS to remove membrane-bound protein,
trypsinized, resuspended in 500 L of full media
and placed on ice. Cells were analyzed on either a
LSRII or Fortessa ﬂow cytometer (BD Biosciences)
for GFP internalization (ex, 488 nm) or mCherry in-
ternalization (ex, 561 nm). Cells were gated for
live cells and at least 5  103 live cells were ana-
lyzed for each treatment. Data was analyzed with
FlowJo software (Tree Star, Inc.)
In Vitro Cre Delivery Assays. HeLa cells were
plated at 3  104 cells per well in 48-well plates.
After 16 h, cells were transfected with pCALNL-
DsRed2 (17) using Effectene transfection reagent
(Qiagen). After incubation with 1001000 nM of
each Cre fusion protein for4hi nserum-free
DMEM, cells were washed three times with 20 U
mL1 heparin in PBS and incubated in full media
for 48 h. Delivery of Cre was assayed by following
DsRed2 expression using ﬂow cytometry and ﬂuo-
rescence microscopy.
Cre reporter 3T3 cells were plated at 1  105
cells per well in 48-well plates. After 16 h, cells
were incubated with various concentrations of pro-
tein for4hi nserum-free media. Cells were
washed with three times with 20 U mL1 heparin
in PBS and incubated in full media for 48 h. Re-
combined cells were quantiﬁed by X-gal staining
and manual counting.
BSR cells were obtained from Matthias Schnell
(Thomas Jefferson University). A pQCXIX MMLV ret-
rovirus (Clontech) containing the tdTomato cre re-
porter construct was generated by subcloning the
tdTomato gene (Clontech) into a pCALNL backbone
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cells were infected with retrovirus and integrants
were selected for 1 week in the presence of 1 mg
mL1 G418 (Sigma). BSR.LNL.tdTomato cells were
plated at 1  105 cells per well in 48-well plates.
After 16 h, cells were incubated with various con-
centrations of protein for4hi nserum-free media.
Cells were washed with three times with 20 U mL1
heparin in PBS and incubated in full media for
48 h.
For chloroquine treatment of BSR cells, cells
were incubated with Cre fusion proteins for4hi n
serum-free media containing 100 M chloroquine,
washed three times with 20 U mL1 heparin in
PBS, and incubated 12 h in full media containing
100 M chloroquine. Following this incubation,
cells were washed once with PBS and incubated
a further 36 h in full media without chloroquine.
Delivery of Cre was assayed by following tdTomato
expression using ﬂow cytometry and ﬂuorescence
microscopy.
For ﬂuorescent Cre reporters, recombinants
were identiﬁed by ﬂow cytometry as those cells of
the live-cell population that exhibited ﬂuorescence
signiﬁcantly higher than that of nontreated re-
porter cells. Typically, the recombined population
exhibited ﬂuorescence at least 10-fold higher than
the nonrecombined cells and were readily de-
tected as a distinct subpopulation. Fluorescence
gates were drawn accordingly to quantitate recom-
bined and nonrecombined cells.
In Vivo Cre Delivery. RC::PFwe mice were ob-
tained from Susan Dymecki (Harvard University).
All of the experiments in this study were approved
by the Institutional Animal Care and Use Commit-
tee at Harvard University. Adult CD1 mice were
subretinally injected with 0.5 Lo f1 0 0M 36
GFP. After 6 h, the retinae were harvested and ana-
lyzed by ﬂuorescence microscopy. RC:PFwe p0
pups were subretinally injected with 0.5 Lo f
40 M wtCre, Tat-Cre, or 36 GFP-Cre. After 72 h,
retinae were harvested and ﬁxed with 0.5% glutar-
aldehyde. Fixed retinae were stained with X-gal
overnight and embedded in 50% OCT, 50% of
30% sucrose and stored at 80 °C. Retinae were
cut into 30 m sections and imaged for X-gal stain-
ing on a Zeiss Axiophot brightﬁeld microscope
with a Nikon CXM-1200F camera. Delivery of Cre
was assayed by manually counting LacZ cells.
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